ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study

Liu, Shuai; Zhao, Liuyuan; Zhou, Guohua*南京大学; 哈尔滨医科大学; 1
Frontiers in Genetics2022-10-20DOI: 10.3389/fgene.2022.1016085
1被引7阅读
引用收藏
分享

摘要

This study aims to investigate the prognostic impact of peripheral blood markers in patients with advanced non-small cell lung cancer (NSCLC) undergoing immunotherapy. In the current multicenter study, 157 advanced NSCLC cases treated by immunotherapy at three institutions were included. Biochemical parameters in baseline peripheral blood were collected. The associations between biochemical parameters and prognosis were investigated by the Kaplan-Meier survival analyses and Cox regression, and the predictive performances of biomarkers were evaluated via receiver operating characteristic analysis. The neutrophil-to-lymphocyte ratio (NLR) (progression-free survival [PFS]: hazard ratio [HR], 1.766; 95% confidence interval [CI], 1.311-2.380; p < 0.001; overall survival [OS]: HR, 1.283; 95% CI, 1.120-1.469; p < 0.001) and red blood cell distribution width (RDW) (PFS: HR, 1.052; 95% CI, 1.005-1.102; p = 0.031; OS: HR, 1.044; 95% CI, 1.001-1.091; p = 0.042) were revealed as independent predictors for both PFS and OS. In addition, NLR & GE;3.79 (1-year PFS, 24.2% [95% CI, 15.2%-38.4%] versus 27.3% [95% CI, 18.2%-41.1%], p = 0.041; 1-year OS, 44.2% [95% CI, 32.5%-60.1%] versus 71.8% [95% CI, 60.6%-85.2%], p < 0.001) or RDW & GE;44.8 g/L (1-year PFS, 19.2% [95% CI, 11.4%-32.3%] versus 31.7% [95% CI, 21.9%-46.0%], p = 0.049; 1-year OS, 54.0% [95% CI, 42.7%-68.3%] versus 63.1% [95% CI, 50.6%-78.6%], p = 0.014) was significantly correlated to poorer PFS and OS than NLR < 3.79 or RDW < 44.8 g/L. Moreover, NLR and RDW achieved areas under the curve with 0.651 (95% CI, 0.559-0.743) and 0.626 (95% CI, 0.520-0.732) for predicting PFS, and 0.660 (95% CI, 0.567-0.754) and 0.645 (95% CI, 0.552-0.739), for OS. Therefore, PLR and RDW could help predict the immunotherapeutic efficacy of advanced NSCLC.

学科与关键词

关键词
non-small cell lung cancerbiomarkerperipheral bloodneutrophil-to-lymphocyte ratiored blood cell distribution width
相关
加载中…
  • Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study
    Yang, Xiongwen; Xiao, Yi; Zhou, Yubin; Deng, Huiyin; Yuan, Zihao; Dong, Longyan; Lan, Jun; Hu, Hao*; Huang, Jian*; Huang, Shaohong*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231206282.
  • Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study
    Huang, Jian; Xiao, Yi; Zhou, Yubin; Deng, Huiyin; Yuan, Zihao; Dong, Longyan; Lan, Jun; Li, Xiane; Liu, Gaijiao; Hu, Hao*; Huang, Shaohong*; Yang, Xiongwen*BMC CANCER, 2023, 23(1): 812.被引 1
  • New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors
    Lin, Xuwen; Chen, Xi; Long, Xiang; Zeng, Chao; Zhang, Zhihan; Fang, Weiyi*; Xu, Ping*Respiratory Research, 2023, 24(1): 64.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Genetics
发表日期
2022-10-20
卷期
第 13 卷
页码
1016085
DOI
10.3389/fgene.2022.1016085
期刊等级
3区
成果收录
SCIE

作者

  • L

    Liu, Shuai (第一作者)

    nanjing univ

  • Z

    Zhao, Liuyuan

    harbin med univ · nanjing univ

查看全部 3 位作者收起作者
  • Z

    Zhou, Guohua (通讯)

    1 · dalian med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417